Topalian et al. [11] chose 5% as the PD-L1 positivity cutoff to assess the role of PD-L1 expression in the response to an anti-PD1 antibody therapy in NSCLC, melanoma, castration-resistant prostate cancer and renal cell cancer. The gene discussed is CD274; the disease is prostate carcinoma.